THIS WEEK
Eli Lilly announced TRIUMPH-1 topline results on May 21. Retatrutide produced 28.3% mean weight loss at 80 weeks and 30.3% at 104 weeks in participants with BMI 35 or higher. That is the largest weight loss number ever recorded in a Phase 3 pharmaceutical trial and sits at the lower end of bariatric surgery outcomes. We break down what the data actually shows, what the topline does not tell you yet, and what comes next for the NDA timeline. On the negative results front, the TESTS Phase 3 trial of thymosin alpha-1 in 1,106 sepsis patients missed its primary mortality endpoint, and we explain what that result means for the compound's other indications. The July FDA advisory panel is now confirmed with a full agenda and a comment deadline of July 9.
Retatrutide TRIUMPH-1: 30.3% Weight Loss at Two Years. The Largest Number Ever Recorded in a Phase 3 Trial.
Eli Lilly and Company. TRIUMPH-1 topline press release. May 21, 2026.
Retatrutide is a once-weekly injectable triple hormone receptor agonist activating GLP-1, GIP, and glucagon receptors simultaneously. TRIUMPH-1 enrolled adults with obesity or overweight and at least one weight-related comorbidity without type 2 diabetes. Primary endpoint: percentage change in body weight at 80 weeks.
At 80 weeks: 28.3% mean weight loss at 12 mg. 19.0% at 4 mg. Discontinuation due to adverse events: 4.1% at 4 mg, 6.9% at 9 mg, 11.3% at 12 mg, versus 4.9% with placebo. The adverse event profile is consistent with the GLP-1 class: gastrointestinal events, mostly mild to moderate, mostly resolving during treatment.
At the 104-week extension in participants with baseline BMI of 35 or higher: 30.3% mean weight loss, averaging 85.0 lbs. That figure sits at the lower end of bariatric surgery outcomes. No pharmaceutical has produced a number like this in a controlled Phase 3 trial before.
Cardiometabolic secondary endpoints were positive: waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and C-reactive protein all improved from baseline.
Two successful Phase 3 readouts are now in hand: TRIUMPH-1 for general obesity and TRIUMPH-4 for obesity with knee osteoarthritis (28.7% weight loss, 75.8% knee pain reduction). Lilly is positioned to file an NDA. Seven additional TRIUMPH readouts are expected in 2026. Full results to be presented at the 86th ADA Scientific Sessions. An NDA filing is anticipated in late 2026 to early 2027.
Full premium section continues: the complete dose-response comparison across TRIUMPH-1 arms, what the 11.3% discontinuation rate at 12 mg means for real-world prescribing, and how TRIUMPH-1 changes the competitive landscape for tirzepatide and CagriSema.
The Dose-Response Picture
The 4 mg arm is the most important number for real-world prescribing. At 19.0% weight loss with a 4.1% discontinuation rate, it produces outcomes competitive with tirzepatide's lower doses at a tolerability profile close to placebo. For patients who cannot tolerate the GI side effects at 12 mg, the 4 mg arm is not a consolation prize. It is a clinically meaningful option.
The 11.3% discontinuation rate at 12 mg is higher than the 4.9% placebo rate and higher than the rates seen at the same dose level in tirzepatide and semaglutide trials. This is a real tolerability signal. The glucagon receptor component, which drives the additional weight loss beyond GLP-1 and GIP, also increases GI adverse events at higher doses. The trade-off between maximum efficacy and tolerability will shape prescribing practice once retatrutide is approved.
How TRIUMPH-1 Changes the Competitive Landscape
Tirzepatide (SURMOUNT-1): 22.5% at 72 weeks. CagriSema (REDEFINE 1): 22.7% at 68 weeks. Retatrutide (TRIUMPH-1): 28.3% at 80 weeks. These are not head-to-head trials and population differences exist, but the directional picture is clear. Retatrutide produces substantially larger weight loss than any currently approved or filed compound.
The REDEFINE 4 head-to-head trial compared CagriSema 2.4/2.4 mg versus tirzepatide 15 mg at 84 weeks and found 23.0% versus 25.5% weight loss per protocol. Tirzepatide outperformed CagriSema head-to-head. Retatrutide's 28.3% at 80 weeks, if it holds in head-to-head trials, positions it above both. TRIUMPH-5 is the active comparator trial that will provide the direct evidence.
NDA Timeline
Late 2026 to early 2027 is the most realistic NDA filing window based on Lilly's published trial schedule. TRIUMPH-2 (T2D) and TRIUMPH-3 (CVD) data are needed for the full label. Assuming a standard 12-month review, FDA approval could come in late 2027 to early 2028. That timeline will compress if Lilly files under priority review based on cardiovascular or metabolic benefit data.
Why the Triple Agonist Mechanism Produces Larger Weight Loss: GLP-1 Plus GIP Plus Glucagon Explained
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
Thymosin Alpha-1 TESTS Failure: What 1,106 Patients and a Negative Phase 3 Tell Us About Immune Modulation in Sepsis
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
FDA PCAC July 23 to 24: Confirmed Agenda, Comment Deadline, and What Advisory Review Actually Means
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use